图片来源:摄图网
近日,港股上市公司德琪医药发布公告称,与翰森制药达成独家合作协议,由翰森制药负责塞利尼索在中国大陆的商业化, 德琪医药将获最高2亿元首付款及最高5.35亿元里程碑付款。
据了解,塞利尼索是德琪医药首个上市商业化产品,从Karyopharm引进,...查看全文
$Karyopharm(KPTI)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001209191-21-035028 Size: 9 KB 网页链接
$Karyopharm(KPTI)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001209191-21-035030 Size: 5 KB 网页链接
$Karyopharm(KPTI)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001209191-21-035031 Size: 9 KB 网页链接
$Karyopharm(KPTI)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001209191-21-031481 Size: 5 KB 网页链接
$Karyopharm(KPTI)$ 内部交易: 2021-05-06,Director,BOHLIN GAREN G ,买入,4000普通股, $7.82
$Karyopharm(KPTI)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001209191-21-031437 Size: 8 KB 网页链接
$Karyopharm(KPTI)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001209191-21-030166 Size: 11 KB 网页链接
$Karyopharm(KPTI)$ 10-Q Quarterly report [Sections 13 or 15(d)] Accession Number: 0000950170-21-000073 Act: 34 Size: 7 MB 网页链接
$Karyopharm(KPTI)$ 8-K Current report, items 2.02 and 9.01 Accession Number: 0001193125-21-146627 Act: 34 Size: 266 KB 网页链接
$Karyopharm(KPTI)$ DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material Accession Number: 0001193125-21-146629 Act: 34 Size: 37 KB 网页链接